miR-129a-3p Inhibits PEDV Replication by Targeting the EDA-Mediated NF-κB Pathway in IPEC-J2 Cells

Xiaoyi Qi1, Yue Cao1, Shenglong Wu1,2

  • 1College of Animal Science and Technology, Yangzhou University, Yangzhou 225000, China.

Insights

MicroRNA-129a-3p inhibits porcine epidemic diarrhea virus (PEDV) replication by targeting the EDA gene and activating the NF-κB pathway. This finding offers potential for disease-resistance breeding in pigs.

Area of Science:

  • Virology
  • Molecular Biology
  • Immunology

Background:

  • MicroRNAs (miRNAs) are implicated in viral infections, but their specific role in porcine epidemic diarrhea virus (PEDV) pathogenesis is not fully understood.
  • Understanding the molecular mechanisms of miRNA regulation during PEDV infection is crucial for developing effective control strategies.

Purpose of the Study:

  • To elucidate the role of miR-129a-3p in regulating PEDV infection in IPEC-J2 cells.
  • To identify the molecular targets and pathways involved in miR-129a-3p-mediated PEDV resistance.

Main Methods:

  • Establishment of a PEDV-infected IPEC-J2 cell model.
  • Expression analysis of miR-129a-3p and the ectodysplasin (EDA) gene.
  • Dual luciferase assay to confirm the binding of miR-129a-3p to the EDA 3'UTR.
  • Transcriptome sequencing to analyze downstream regulatory mechanisms.
  • Investigation of the NF-κB pathway activation.

Main Results:

  • PEDV infection significantly downregulated miR-129a-3p expression in IPEC-J2 cells.
  • Overexpression of miR-129a-3p inhibited PEDV replication, while its silencing promoted viral replication.
  • miR-129a-3p directly targets the 3'UTR of the EDA gene, reducing its expression.
  • Upregulation of EDA expression enhanced PEDV replication.
  • miR-129a-3p activates the CARD11-mediated NF-κB pathway, inhibiting PEDV replication.

Conclusions:

  • miR-129a-3p acts as a negative regulator of PEDV replication in porcine intestinal epithelial cells (IPEC-J2).
  • The mechanism involves targeting the EDA gene and activating the NF-κB signaling pathway.
  • These findings provide a basis for utilizing miR-129a-3p in breeding programs for PEDV resistance.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
8.0K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K